EyeGene Statistics
Total Valuation
EyeGene has a market cap or net worth of KRW 88.93 billion. The enterprise value is 61.16 billion.
Market Cap | 88.93B |
Enterprise Value | 61.16B |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
EyeGene has 27.03 million shares outstanding. The number of shares has increased by 17.55% in one year.
Current Share Class | 27.03M |
Shares Outstanding | 27.03M |
Shares Change (YoY) | +17.55% |
Shares Change (QoQ) | +0.15% |
Owned by Insiders (%) | 6.59% |
Owned by Institutions (%) | 0.07% |
Float | 19.44M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 24.36 |
PB Ratio | 1.79 |
P/TBV Ratio | 2.05 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -5.10 |
EV / Sales | 16.75 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -7.36 |
Financial Position
The company has a current ratio of 3.47, with a Debt / Equity ratio of 0.05.
Current Ratio | 3.47 |
Quick Ratio | 3.38 |
Debt / Equity | 0.05 |
Debt / EBITDA | n/a |
Debt / FCF | -0.30 |
Interest Coverage | -17.42 |
Financial Efficiency
Return on equity (ROE) is -23.02% and return on invested capital (ROIC) is -13.28%.
Return on Equity (ROE) | -23.02% |
Return on Assets (ROA) | -11.29% |
Return on Invested Capital (ROIC) | -13.28% |
Return on Capital Employed (ROCE) | -22.89% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.05 |
Inventory Turnover | 7.78 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.48% in the last 52 weeks. The beta is 1.61, so EyeGene's price volatility has been higher than the market average.
Beta (5Y) | 1.61 |
52-Week Price Change | +12.48% |
50-Day Moving Average | 3,196.60 |
200-Day Moving Average | 3,015.63 |
Relative Strength Index (RSI) | 51.48 |
Average Volume (20 Days) | 120,305 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EyeGene had revenue of KRW 3.65 billion and -12.00 billion in losses. Loss per share was -443.71.
Revenue | 3.65B |
Gross Profit | 1.15B |
Operating Income | -12.18B |
Pretax Income | -12.53B |
Net Income | -12.00B |
EBITDA | -9.78B |
EBIT | -12.18B |
Loss Per Share | -443.71 |
Balance Sheet
The company has 32.35 billion in cash and 2.53 billion in debt, giving a net cash position of 29.82 billion or 1,103.28 per share.
Cash & Cash Equivalents | 32.35B |
Total Debt | 2.53B |
Net Cash | 29.82B |
Net Cash Per Share | 1,103.28 |
Equity (Book Value) | 49.55B |
Book Value Per Share | 1,761.95 |
Working Capital | 24.41B |
Cash Flow
In the last 12 months, operating cash flow was -6.80 billion and capital expenditures -1.51 billion, giving a free cash flow of -8.31 billion.
Operating Cash Flow | -6.80B |
Capital Expenditures | -1.51B |
Free Cash Flow | -8.31B |
FCF Per Share | -307.57 |
Margins
Gross Margin | 31.47% |
Operating Margin | -333.62% |
Pretax Margin | -343.34% |
Profit Margin | n/a |
EBITDA Margin | -268.00% |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
EyeGene does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -17.55% |
Shareholder Yield | n/a |
Earnings Yield | -13.49% |
FCF Yield | -9.35% |
Stock Splits
The last stock split was on June 28, 2021. It was a forward split with a ratio of 1.2.
Last Split Date | Jun 28, 2021 |
Split Type | Forward |
Split Ratio | 1.2 |
Scores
EyeGene has an Altman Z-Score of -0.24. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.24 |
Piotroski F-Score | n/a |